Sudeep Pharma reports cessation of SMP Sendhil Pani
- Mr. Sendhil Pani ceased to be Senior Management Personnel effective October 2, 2026
- Departure attributed to completion of contractual arrangements with Sudeep Pharma
- Mr. Pani served as Managing Director of wholly owned subsidiary Sudeep Pharma USA Inc.
- Disclosure filed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
*this image is generated using AI for illustrative purposes only.
Sudeep Pharma Limited announced the cessation of Mr. Sendhil Pani from the position of Senior Management Personnel (SMP) effective October 2, 2026. The departure follows the completion of contractual arrangements between the company and Mr. Pani.
Mr. Pani served as the Managing Director of Sudeep Pharma USA Inc., a wholly owned subsidiary of Sudeep Pharma. His role as an SMP under SEBI Listing Regulations concluded on the specified date.
Regulatory disclosure details
The company filed this information with the National Stock Exchange of India and BSE pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.
| Detail | Information |
|---|---|
| Name | Mr. Sendhil Pani |
| Role | Managing Director, Sudeep Pharma USA Inc. |
| Reason for change | Completion of contractual arrangements |
| Effective date | October 2, 2026 |
Corporate governance context
Sudeep Pharma confirmed that Mr. Pani will no longer be associated with the company as SMP in accordance with Regulation 16(1)(d) of the SEBI Listing Regulations. The filing was signed by Dimple Ashwinbhai Mehta, Company Secretary & Compliance Officer, on October 5, 2026.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.20% | +2.62% | -4.67% | +91.11% | +51.57% | +51.57% |
Who has been appointed as the successor to Mr. Sendhil Pani as Managing Director of Sudeep Pharma USA Inc.?
How will the leadership transition at the US subsidiary impact Sudeep Pharma's ongoing regulatory filings with the US FDA?
What are the immediate financial implications of the contractual completion on Sudeep Pharma's quarterly operational costs?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
